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S U M M A R Y
This position paper is the second ESCMID Consensus Document on this subject and aims to provide
intensivists, infectious disease specialists, and emergency physicians with a standardized approach to
the management of serious travel-related infections in the intensive care unit (ICU) or the emergency
department. This document is a cooperative effort between members of two European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) study groups and was coordinated by Hakan
Leblebicioglu and Jordi Rello for ESGITM (ESCMID Study Group for Infections in Travellers and
Migrants) and ESGCIP (ESCMID Study Group for Infections in Critically Ill Patients), respectively. A
relevant expert on the subject of each section prepared the first draft which was then edited and
approved by additional members from both ESCMID study groups. This article summarizes
considerations regarding clinical syndromes requiring ICU admission in travellers, covering
immunocompromised patients.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Over the last 20 years, the increase in international travel, which
has been intensified by the availability of low-cost flights, has
facilitated the movement of an increased number of patients from
areas with endemic diseases to distant regions. As a consequence,
cities around flight hubs have been and are exposed to the rapid
dissemination of imported infections, as was reported in the initial
dissemination of HIV infection in North America, and more recently
in the 2009 influenza pandemic. Similarly, outbreaks of choleraDOI of original article: http://dx.doi.org/10.1016/j.ijid.2016.04.019
§ ESGCIP is the ESCMID Study Group for Infections in Critically Ill Patients;
ESGITM is the ESCMID Study Group for Infections in Travellers and Migrants.
* Corresponding author. Tel.: +41 79 556 61 36.
E-mail address: oriol.manuel@chuv.ch (O. Manuel).
http://dx.doi.org/10.1016/j.ijid.2016.04.020
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).have been reported in travellers after long distance flights, and
tourism has also been associated with the dissemination of
infections such as measles, rubella, diphtheria, typhoid fever, and
chicken pox, in addition to malaria and haemorrhagic fevers. Poor
health conditions and crowding are associated with tuberculosis
(TB), diarrhoea, tetanus, and other infectious events, which may
be imported by migrants from areas devastated by war.
Immunocompromised patients encompass a growing population
with increased susceptibility to infectious complications. Because
they live longer and have a better quality of life than ever before, they
may have more opportunity to travel and potentially encounter
travel-associated infections. It has been estimated that up to one
third of solid-organ transplant (SOT) recipients may travel to
resource-limited countries within the first year post-transplant.1
In a survey in North American transplant centres, up to 44% of
haematopoietic stem cell transplant (HSCT) recipients reported
travel outside the USA and Canada after transplantation.2 Aociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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migrants who may return to their countries of origin to visit friends
and relatives, and may acquire travel-associated infections. The
increased use of monoclonal antibodies for therapy in immunologi-
cal and oncological diseases has created another at-risk population,
although the actual risk of travel-associated infection in these
patients is not well established.3 Data on the real risk of infection
in immunocompromised travellers relative to the general travel
population are scarce,4 and particularly the risk of developing an
illness severe enough to warrant admission to an intensive care unit
(ICU). The repatriation of immunocompromised patients from
hospitals in destination countries also carries the risk of contami-
nation of the receiving hospital with multidrug-resistant (MDR)
microorganisms, which requires specific infection control mea-
sures.5 This article also addresses certain specific syndromes, such
as pneumonia and acute respiratory distress syndrome (ARDS)
occurring after travel.
This position paper is the second ESCMID Consensus Document
on this subject and aims to provide intensivists, infectious disease
specialists, and emergency physicians with a standardized approach
to the management of serious travel-related infections in the ICU
or emergency department. This document is a cooperative effort
between members of two European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) study groups and was coordinated
by Hakan Leblebicioglu and Jordi Rello for ESGITM (ESCMID Study
Group for Infections in Travellers and Migrants) and ESGCIP (ESCMID
Study Group for Infections in Critically Ill Patients), respectively.
A relevant expert on the subject of each section prepared the first
draft, which was then edited and approved by additional members
from both ESCMID study groups. This article summarizes consider-
ations regarding clinical syndromes requiring ICU admission in
travellers, covering immunocompromised patients.Table 1
Infectious risk according to type of immunosuppression
Infectious risk Typ
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SOT recipients 1st month post-transplantation: risk related with

























After 1st year post-transplantation: non-
significant immunosuppression >2 years
Oncological patients After recent chemotherapy or radiotherapy





Splenectomized patients Particularly during the first 2 years, but may






During therapy and a month after





GVHD, graft versus host disease; HCV, hepatitis C virus; HSCT, haematopoietic stem ce
syncytial virus; SOT, solid-organ transplant; TNF, tumour necrosis factor.2. Risk of infection in immunocompromised patients (Table 1)
2.1. Solid-organ and haematopoietic stem cell transplantation
The risk of infection in SOT recipients varies according to
multiple factors, namely the type of organ transplanted, the time
from transplantation, and the type and dose of immunosup-
pressive drugs received.6 During the first month post-transplant,
infectious complications are mainly healthcare-associated. The
most profound immunosuppression occurs between months 2 to
6; historically, this is the period in which most opportunistic
infections were diagnosed, including herpesvirus infections
(cytomegalovirus), Pneumocystis jirovecii pneumonia, and inva-
sive fungal infections.7 However, with the use of universal
antiviral preventive strategies and long-term co-trimoxazole
prophylaxis, opportunistic infections are currently rarely seen.
After 6–12 months, the risk of infection decreases significantly
and infections over this period are usually community-acquired,
except in the case of increased immunosuppression (due to
allograft rejection or dysfunction) or in the case of chronic
surgical complications. Because the incidence of infection is
higher early after transplantation, it is recommended to avoid
travel during the first year.8
HSCT recipients are at increased risk for bacterial and fungal
infections during the engraftment period in the first month post-
transplant. In the case of graft-versus-host disease, cellular
immunosuppression is the mechanism responsible for the
development of viral infections (particularly cytomegalovirus,
adenovirus, and BK virus) and invasive fungal infections.9 After the
second year post-transplant it is considered that the degree of
immunosuppression is non-significant if the patient has not
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Tuberculosis, skin and soft tissue infection, zoster
ll transplant; HSV, herpes simplex virus; ICU, intensive care unit; RSV, respiratory
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While the use of biological agents for the therapy of
rheumatological and autoimmune diseases has increased consid-
erably over recent years, data on the risk of infection are mainly
limited to the use of anti-tumour necrosis factor (TNF) agents.
Several large cohort studies found patients receiving anti-TNF
therapy to be at greatest risk of developing skin infections,
although the overall risk of severe infections was similar to that of
patients receiving other non-biological therapies.10 A study from
the Netherlands assessed the risk of infection in 75 travellers
receiving biological agents relative to their travelling companions.4
Immunocompromised patients were at significantly higher risk of
developing skin infections, fatigue, and abdominal pain, but not
fever, diarrhoea, or respiratory infections. Of note, no serious
infection developed during or after the trip in these patients.
Patients on anti-TNF therapy have an increased risk of developing
mycobacterial infections, with several cases of disseminated TB
with a fatal outcome reported in the literature.11 Cutaneous
leishmaniasis has also been reported in patients on anti-TNF
treatment.12
2.3. Oncological patients
The risk of bacterial and fungal infections in patients with an
oncological condition is increased during the administration of
chemotherapy and/or radiotherapy and/or immunotherapy, par-
ticularly during the period of neutropenia.13 In contrast, the risk of
infection is generally considered not to be increased some months
after the conclusion of chemotherapy and in patients receiving
hormone therapy. Patients with haematological conditions, such
as lymphoma or Hodgkin disease, may, however, have some degree
of cellular immunosuppression even months after the remission
of the disease.
2.4. Asplenic patients
Asplenic patients are at significantly higher risk of infection
with encapsulated bacteria, namely Streptococcus pneumoniae,
Neisseria meningitidis, Haemophilus influenzae, and Capnocytophaga
canimorsus.14 Thus, appropriate vaccination with conjugated
vaccines is an essential preventive strategy in these patients.
Other potentially life-threatening infections that are more
common in asplenic patients include salmonellosis, babesiosis,
and malaria. While the risk of infection is higher during the first
month following splenectomy, the increased risk persists for years.
The risk of infection in asplenic patients depends on the underlying
condition, being higher in patients with haematological diseases
and in those in whom immunization may not be fully successful
or is associated with suboptimal protection over long periods of
time. Such patients may be instructed to start empirical antibiotics
targeted at encapsulated bacteria immediately if any clinical signs
or symptoms of infection ensue.15
3. Travel-related infections in immunocompromised patients
3.1. Malaria
There are few studies that have addressed the epidemiology
and clinical manifestations of malaria in immunocompromised
patients. The incidence of malaria was reported to be less than 1%
in HSCT recipients in an endemic country (Pakistan); however,
data on other immunosuppressive conditions and in travellers are
missing.15 Despite the lack of prospective studies, it appears that
malaria is associated with more severe outcomes in immunocom-
promised patients than in the general population. A recentsystematic review found that up to 45% of published cases of
malaria in SOT recipients had at least one criterion for severe
malaria (O. Manuel, personal communication). Importantly,
malaria may develop through transmission from the organ donor,
and as such there may not be a travel history.16 A case of cerebral
malaria with >50% parasitemia has been reported in a patient
receiving infliximab;17 however such severe disease can occur in
patients not on biologicals as well. Malaria can also be more severe
in splenectomized patients due to the lack of clearance of intra-
erythrocytic parasites.
The successful treatment of severe malaria in immunocompro-
mised patients has been reported with the use of erythropheresis
and artesunate.18 The choice of the preventive strategy for malaria
in immunocompromised travellers should be individualized,
favouring antimalarial prophylaxis in patients travelling to
intermediate-risk and high-risk regions.
3.2. Dengue
Several cases of severe dengue in immunocompromised
patients have been reported, mostly in patients in endemic
countries. In a series of kidney transplant recipients in India, up to
37% of patients diagnosed with dengue had a severe course and
died.19 All presented with fever, thrombocytopenia, myalgia, and
retro-ocular pain. In contrast, in a series of eight patients receiving
biologicals who were diagnosed with dengue, none developed
severe infection.20 Dengue fever was reported to be a frequent
cause of febrile neutropenia in haematological patients in India,
but this was not associated with worse outcomes.21 Early diagnosis
is essential in immunocompromised travellers with clinical
manifestations suggestive of dengue in order to initiate early
appropriate supportive therapy. Aggressive volume replacement
within the first 24 h of ICU admission is important to limit the
development of multiple organ dysfunction syndrome and
increase the probability of survival.
3.3. Fungal infections
Travel-related fungal infections in immunocompromised
patients are uncommon, but potentially associated with a severe
course and increased mortality.22 Invasive travel-related fungal
infections that have manifested with a severe course in SOT
recipients and HIV-infected individuals include disseminated
Penicillium marneffei infection, aspergillosis, histoplasmosis, and
coccidioidomycosis.23 In patients receiving monoclonal antibodies,
severe travel-associated histoplasmosis has been associated with a
50% mortality rate, and in another report, malignancy was a risk
factor for acquiring a Cryptococcus gattii infection.24 Importantly
some of these infections may have a long incubation period so the
travel history may be underreported. As such, a detailed travel
history should be sought in immunocompromised travellers who
develop fever associated with pulmonary lesions and/or localized
cutaneous or subcutaneous disease, and these patients should
be investigated promptly and aggressively for the diagnosis of
invasive fungal infections.22
3.4. Other infections
The risk of TB is increased in transplant patients, HIV-infected
individuals, and in patients receiving biologicals, but the risk of
travel-acquired TB in immunocompromised patients is not well
established. Screening for latent TB infection after travel to
endemic regions in these patients might, however, identify
patients at risk of developing active TB. Leptospirosis is a common
cause of fever in returning travellers, and can be associated with
severe complications. In a series of nine HIV-infected patients with
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was 22%.25 Data on the severity of leptospirosis in other
immunocompromised populations are lacking. Nocardiosis in
SOT recipients is associated with a high incidence of disseminated
disease, particularly with central nervous system involvement.
Strongyloidiasis in immunocompromised patients is a rare but
potentially life-threatening condition. Donor-derived or travel-
acquired infestation with Strongyloides stercoralis is associated
with a high mortality.26 Cases of Chagas disease (Trypanosoma
cruzi) either as a consequence of reactivation of a latent infection
not identified at the time of transplant (because an unrecorded
travel history or stay in an endemic area) or by transmission
through the organ donor, can also be associated with a high
mortality.27 Furthermore, immunocompromised patients may be
particularly susceptible to severe forms of West Nile virus infection
and tick-borne encephalitis, all of which should be actively sought
in the workup of patients with central nervous system symptoms
after returning from endemic areas. There have also been case
reports of severe disease from other travel-associated infections,
such as salmonellosis, Vibrio parahaemolyticus, and visceral
leishmaniasis in immunocompromised patients.
4. Acute respiratory distress syndrome (ARDS) in returning
travellers
There are many causes of respiratory failure and of ARDS. Those
that are specific to certain geographic regions and that may appear
unexpectedly in travellers are less common, but are nevertheless
extremely important because appropriate therapy requires a
correct diagnosis, and some infections may have epidemic
potential. The infectious causes in particular may not be
recognized immediately because they may be out of their usual
geographical context. Those that can cause ARDS will be discussed
briefly below. Table 2 summarizes the main recommended
antimicrobial regimens for specific organisms involved in ARDS
in returning travellers.
4.1. Community-acquired pneumonia (CAP)
CAP is the most likely cause of acute respiratory failure in
returning travellers. The usual pathogens, such as S. pneumoniae, H.
influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae,
Legionella pneumophila, and viruses such as influenza andTable 2
Recommended antimicrobial therapy for specific organisms involved in acute respirato
Recommended regimen Alternat
Streptococcus pneumoniae Penicillin Second- 









Legionella pneumophila Quinolone or macrolide 
Pseudomonas aeruginosa Piperacillin–tazobactam, fourth-
generation cephalosporins or
carbapenems  aminoglycoside or
quinolones
Colistin i





Influenza Oseltamivir, inhaled zanamivir IV peram
severe in
RSV None Oral or i
IV, intravenous; PVL, Panton–Valentine leukocidin; MDR, multidrug-resistant; RCT, ranrespiratory syncytial virus, are the most common culprits.
However aspiration must be considered in the elderly and in
those who have become inebriated whilst on holiday. Less
common pathogens such as Staphylococcus aureus, avian influenza
viruses such as H7N9 and H5N1, the Middle East respiratory
syndrome coronavirus (MERS-CoV), and Gram-negative rods such
as Burkholderia pseudomallei must also be considered, as well as a
few other pathogens that do not usually cause pneumonia, such as
malaria.
4.2. Influenza
Influenza viruses such as H1N1 and H3N2, which are currently
circulating, are perhaps the most common travel-related infec-
tions, particularly in the unvaccinated, those travelling across
hemispheres, and where the available vaccine does not cover a
particular strain effectively. Influenza is an acute illness mani-
fested by pyrexia, cough, chills, myalgia, and fatigue. There can,
however, be more severe complications, specifically pneumonia,
especially in pandemic years. In the 2009 influenza
A(H1N1)pdm09 pandemic, more than 18 500 deaths were
reported, with global estimates 15 times higher. The primary risk
factors were age (young to middle age; >60% were aged <65
years), morbid obesity, pregnancy, and an immunocompromised
status. Influenza also increases the risk of bacterial pneumonia,
particularly that caused by S. pneumoniae and S. aureus. Those with
severe disease deteriorate acutely after 4–5 days, with profound
hypoxemia, shock, and often multiple organ dysfunction syn-
drome. The pathological findings are of an intense inflammatory/
haemorrhagic pneumonia, the severity of which seems to be
influenced by the presence or absence of associated bacterial
CAP.28
Any patient with the above features, particularly if unvaccinat-
ed or having travelled to another hemisphere during the winter
season, should be investigated for influenza, with diagnosis based
on throat swab or nasal wash and a commercial kit based on
antigen or RT-PCR.29 Unfortunately there is very low uptake of
influenza vaccine even amongst healthcare workers, and as such
there remains a large pool of susceptible individuals.
Although not yet reported to have been transmitted from
humans, avian influenza H5N1 and H7N9 remain a potential
threat, particularly in Southeast Asia. Travellers who have had
contact with birds in the affected areas and who present withry distress syndrome (ARDS) in returning travellers
ive regimen Comments






Add clindamycin or linezolid in case of
suspicion of PVL-producer
Do not use daptomycin for S. aureus
pneumonia
Despite the absence of RCTs, quinolones
are usually recommended over macrolides
for severe infections
n case of infection by MDR strains Ceftolozane–tazobactam could be an
option for therapy of MDR organisms




ivir or IV zanamivir in case of
fection
Start as soon as possible, empirically in
severe cases
nhaled ribavirin
domized controlled trial; RSV, respiratory syncytial virus.
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reported from 17 countries and is currently most prevalent in
Egypt.30
4.3. Staphylococcus aureus
Staphylococcus aureus pneumonia is usually a fulminant disease
associated with rapid onset respiratory failure, frequently pro-
gressing to multiple organ dysfunction, shock, and death.
Complications are frequent and include pulmonary necrosis and
abscess and empyema formation, particularly if the strain is a
producer of Panton–Valentine leukocidin (PVL) toxin, a cytotoxin
responsible for leukocyte destruction and tissue necrosis. Risk
factors are colonization or infection with S. aureus and a preceding
influenza-like illness (ILI). Leucopenia (2.5  109/l) is characteristic
and may be an inverse biomarker of PVL burden.31
Both methicillin-sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA) can cause CAP. The latter is primarily a
problem of recognition, as the organism is not prevalent in all
countries and standard guideline-based therapies for pneumonia
do not cover MRSA. The sensitivity profile of community-acquired
MRSA differs from that of hospital-acquired MRSA in that it may be
susceptible to macrolides, quinolones, clindamycin, and trimetho-
prim–sulfamethoxazole. Therapy consists of appropriate antimi-
crobial therapy such as linezolid (possibly in preference to
vancomycin, particularly if the strain is a PVL-producer), vanco-
mycin, or ceftaroline.32
4.4. Legionnaires’ disease (legionellosis)
Pneumonia is the most common presentation of legionnaire’s
disease or legionellosis, and it may be severe, leading to multi-
organ failure and death. Characteristic clinical findings are relative
bradycardia, hyponatremia, elevation in serum creatinine kinase,
diarrhoea, confusion, and impaired liver and kidney function.33
The recommended treatment regimen is macrolides or fluoroqui-
nolones.34
4.5. Middle East respiratory syndrome coronavirus (MERS-CoV)
Ten years after the severe acute respiratory syndrome (SARS)
epidemic that affected almost 8000 people and caused 775 deaths,
MERS-CoV, a new coronavirus of the same family, appeared in
Saudi Arabia and subsequently spread to nine countries in or near
the Arabian Peninsula and 14 countries elsewhere.35 On March 10,
2015, the World Health Organization global case count was
1060 laboratory-confirmed cases with 394 deaths (37%). All cases
were resident in or had travelled to the Middle East, most to Saudi
Arabia, or had been in contact with travellers returning from these
areas. MERS-CoV differs from SARS-CoV in that it binds to different
receptors, and camels are thought to be the primary reservoir host,
although the means of transmission from these animals is poorly
understood. Whereas transmission can occur between humans,
the epidemic potential appears to be less. The disease is not always
severe and symptoms range from an ILI to severe pneumonia
requiring mechanical ventilation. The most severely affected
patients have mostly had comorbidities such as diabetes, renal
failure, and chronic lung disease, or have been immunocompro-
mised.36 There is no specific antiviral treatment available for
MERS-CoV infection. Management is primarily supportive, direct-
ed towards the prevention of respiratory complications and
infection control. Corticosteroids are not currently recommended
in this setting.
It is still advised that those travelling to the Middle East and
who are at increased risk of severe disease should avoid contact
with camels and their secretions, and avoid drinking raw camelmilk (which will also prevent infection with Brucella). All travellers
should practice good hand and food hygiene, particularly where
camels are present.
4.6. Gram-negative pathogens
A number of Gram-negative pathogens may cause pneumonia
and ARDS, in particular in relation to aspiration, or in association
with ventilation where pathogens such as Pseudomonas aeruginosa,
Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and
other Enterobacteriaceae are of concern.37 The latter include the
extended-spectrum beta-lactamase (ESBL)- and carbapenemase-
producers (such as those producing New Delhi metallo-b-
lactamase 1 (NDM-1)), which may be acquired during ‘medical
tourism’.38 Diagnosis requires a high index of suspicion and testing
for the specific genes responsible for enzyme production.
Treatment remains a challenge due to deficiencies in the antibiotic
pipeline.
4.7. Melioidosis
Burkholderia pseudomallei is also a Gram-negative bacillus
endemic in Southeast Asia, northern Australia, and possibly the
Indian subcontinent, southern China, Hong Kong, and Taiwan.
Infection results from inoculation of contaminated soil and surface
water through skin abrasions, with subsequent haematogenous
spread. Horizontal transmission also occurs, as well as transmis-
sion through the inhalation of polluted water. It is the most
common cause of fatal community-acquired bacteraemia and
pneumonia in certain areas of north-eastern Thailand, as well as in
Darwin, Australia.39 Travellers from endemic areas, especially in
the wet season and particularly if there are comorbidities, are at
risk. Variable disease severity and the range of presentations
(pneumonia, abscesses, osteomyelitis, and arthritis) make diagno-
sis a challenge. About 50% of patients present with pneumonia
(which may appear as nodular infiltrates or air space consolida-
tion), often with septic shock. The diagnosis is made when B.
pseudomallei is cultured, but specific media are required. Cefta-
zidime or meropenem with or without high-dose co-trimoxazole
are the drugs of choice.
4.8. Tuberculosis
Although TB may occur in any patient, it seldom causes
respiratory failure over a short period of time. Yet, a recent
prospective study from South Africa reported that 1.5% of adults
with active TB may require mechanical ventilation because of
refractory hypoxemia, which in high TB prevalence countries
translates into a significant burden of disease.40 In this setting,
15% of TB suspects had confirmed TB, and it should be
considered if the travel history involves relevant exposure.
Standard smear microscopy or culture are used for diagnosis, or
rapid PCR if available (GeneXpert MTB/RIF), which has been
shown to have increased sensitivity and shorten the time to
treatment.41 Where there is a high clinical suspicion of TB,
empiric therapy should be initiated after adequate sampling has
been obtained, particularly in the case of life-threatening or
disseminated infection. Initial therapy with four drugs (isonia-
zid, rifampicin, pyrazinamide, and ethambutol) is generally
recommended where there is a low prevalence of resistance, and
depending on the patient’s origin and the results of the rapid
detection of rpoB gene mutations. Patients with MDR- or XDR-TB
need to be treated with second-line agents including aminogly-
cosides, quinolones, para-aminosalicylic acid, cycloserine, and
clofazimine, and new drugs such as bedaquiline, linezolid, and
delamanid.
Figure 1. Ecchymosis in meningococcal septicaemia.
Figure 3. Septic embolisms from left-sided endocarditis.
Figure 2. Gangrene complicating Staphylococcus aureus septicaemia.
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Malaria, which is a frequent travel-related disease, may also
lead to ARDS in severely affected patients.41 Increased alveolar
capillary permeability may result in pulmonary oedema and
respiratory failure either at presentation or after treatment.
Pregnant women are particularly at risk. Slide microscopy and
rapid antigen tests are the standard diagnostic tools, and the
treatments of choice are the parenteral artemisinins, although
resistance is emerging.
4.10. Differential diagnosis
Non-infectious causes of bilateral pulmonary infiltrates with
respiratory failure must be differentiated from infectious causes.
These include cardiogenic pulmonary oedema, inflammatory
pulmonary diseases such as cryptogenic organizing pneumonia
(COP) and fibrosis, alveolar haemorrhage (including idiopathic
granulomatous polyangiitis, lupus, and vasculitis), and ARDS from
conditions such as eosinophilic pneumonia, pancreatitis, inhala-
tional injury, and trauma. To identify these, clinical expertise is
critical, along with the use of biomarkers (such a C-reactive
protein, procalcitonin, and pro-B-type natriuretic peptide), serolo-
gy to exclude autoimmune diseases, and imaging including
echocardiography.
4.11. Rescue therapies for ARDS
If mechanical ventilation alone is inadequate, the use of
neuromuscular blockade, recruitment techniques including prone
ventilation, and veno-venous extracorporeal membrane oxygen-
ation (ECMO) may improve oxygenation and the outcome.
4.12. Scoring systems for the stratification of patients with severe
infection
The Berlin classification of ARDS severity is universally accepted
and should be utilized to determine the site of therapy.42 The
Acute Physiology and Chronic Health Evaluation (APACHE) score
provides additional information regarding ICU and hospital
outcomes.43 For pneumonia, the most frequently used scores are
the pneumonia severity index (PSI) and CURB-65. To evaluate
mortality risk in TB patients, the TBscore is useful and has been
shown to predict the outcome.44
5. Fever with haemorrhagic manifestations
Haemorrhagic symptoms and fever can be caused by many
infections due to bacteria, viruses, and parasites. Disseminated
intravascular coagulation (DIC) may be a manifestation of severe
septicaemia and can be caused by almost all Gram-positive and
Gram-negative bacteria. DIC is particularly present in septicaemia
with N. meningitidis (Figure 1), but is also seen in patients with
S. aureus and S. pneumoniae bloodstream infections (Figures 2
and 3). Numerous viruses may also cause haemorrhagic symptoms,
and these include dengue virus, Crimean-Congo haemorrhagic
fever virus, Ebola virus, Yellow fever virus, Hanta virus, and others
(Table 3).
5.1. Isolation and patients with haemorrhagic symptoms at admission
It is most important to establish whether the patient has a
history of travel within the past 4 weeks to areas where viral
haemorrhagic fevers are endemic immediately at admission
(Table 3). If the history and the clinical features are suggestive,
Table 3
Distribution and endemicity of viral haemorrhagic fevers
Countries where outbreaks have
occurred
Countries with evidence of endemicity,
through sporadic cases or seroprevalence
studies
Countries/areas with a theoretical risk
based on geography, but no reports of
cases
Ebola and Marburg Republic of Congo, Democratic Republic
of Congo, Gabon, Ivory Coast, Sudan,
Uganda, Liberia, Sierra Leone, Guinea
Central, Western, and East African
countries
Tropical Africa South of the Sahara
Marburg Angola, Democratic Republic of Congo,
Kenya, Uganda, South Africa, Zimbabwe
Zimbabwe Central and East African countries
Lujo South Africa (ex-Zambia) - -
Lassa Guinea, Liberia, Nigeria, Sierra Leone Benin, Burkina Faso, Ghana, Ivory Coast,
Mali, Togo
Cameroon, Central African Republic,
other West African countries
CCHF Bulgaria, China, Iraq, Iran, Kazakhstan,
Kosovo, Mauritania, Oman, Pakistan,
Russia, South Africa, Tajikistan, Turkey,
United Arab Emirates, Uganda,
Uzbekistan
Benin, Burkina Faso, Egypt, France,
Greece, Hungary, India, Kenya, Portugal,
Tanzania, Zaire
Africa, Balkans, Central Asia, Eastern
Europe, Middle East
Hantaviruses Bosnia, Serbia, Greece (Dobrava), China,
Russia, Korea (Hantaan), Scandinavia,
Russia, Western Europe (Puumala),





(Guanarito), Brazil (Sabia), Bolivia
(Machupo, Chapare)
- -
Kyasanur Forest disease India - -
Alkhurma haemorrhagic fever Saudi Arabia - -
Omsk haemorrhagic fever Russia - -
Dengue haemorrhagic fever Asia, South America, Tropical Africa - Southern Europe
CCHF, Crimean-Congo haemorrhagic fever.
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patient should be evaluated as to whether isolation is necessary.
In most countries where haemorrhagic fever viruses occur,
malaria is also endemic, and a malaria test (rapid diagnostic test or
microscopy) should be performed immediately and at the same
time as blood cultures for bacterial infections are obtained. Once
malaria has been excluded, treatment should be started to cover a
broad range of bacterial infections until such time as the diagnosis
is confirmed. An example of gangrene related to severe staphylo-
coccal septicaemia is shown in Figure 2.
5.2. Rapid assessment
Rapid assessment of the patient and isolation are key to limiting
healthcare-associated transmission. The MERS-CoV outbreak in
South Korea illustrates how rapidly infections can spread in
overcrowded hospitals.45 Most MERS-CoV cases in Saudi Arabia
have also been linked to transmission in hospitals,46 as was the
case with SARS-CoV47 and with Crimean-Congo haemorrhagic
fever.48 Training of paramedical staff, nurses, and physicians, as
well as guidelines for the recognition and rapid assessment of
febrile patients at the initial point of contact, are essential, as is an
isolation area for febrile patients with a relevant travel history.
5.3. Disseminated intravascular coagulation
DIC is an acquired condition of the vascular system leading to an
uncontrolled systemic activation of the coagulation pathway. TheTable 4
Questions to be asked if the patient has travelled in an area where haemorrhagic feve
Does the patient have a fever (>38 8C) or history of fever in the previous 24 hours?
AND
Has the patient cared for/come into contact with body fluids of/handled clinical spec
from a live or dead individual or animal known or strongly suspected to have VHF
Has the patient received a tick bite and/or crushed a tick with their bare hands and/
with livestock or ticks is possible in a CCHF endemic area?
Has the patient lived or worked in basic rural conditions where Lassa, Ebola, or Mar
Has the patient travelled to any local area where a VHF outbreak has occurred?
CCHF, Crimean-Congo haemorrhagic fever; VHF, viral haemorrhagic fever.generation of thrombin and fibrin may cause thrombotic occlu-
sions of blood vessels, and hence organ injury and failure.49 This is
accompanied by an inflammatory reaction, further augmenting the
coagulation process.
DIC frequently accompanies systemic inflammatory response
syndrome (SIRS), severe sepsis, trauma, and other conditions
as diverse as anaphylaxis and heat stroke.49–54 The systemic
activation of the clotting system is associated with the
consumption of both coagulation factors and platelets, and as
such, various combinations of platelet count, prothrombin time,
activated partial thromboplastin time (aPTT), a decrease in
anti-thrombin (AT) and protein C, as well plasma levels of fibrin
and D-dimers have been used for the diagnosis.55 A more
standardized approach can be achieved by using the scoring
system of the International Society of Thrombosis and Haemos-
tasis.56
The successful therapy of DIC is only possible when the
underlying cause is identified and treated. The substitution of
coagulation factors is currently unclear due to the lack of
appropriate randomized placebo-controlled trials. The use
of antifibrinolytics during DIC should be avoided, as this
drug class may lead to the deposition of fibrin in the vascular
walls.57
Overall, the prevalence of DIC during viral haemorrhagic fever is
high and contributes to morbidity and mortality. Early and
effective treatment against the viral infection, if available, reduces
the detrimental complications of DIC. Parameters for assessing DIC
and haemolysis are provided in Table 5.r occurs
imens (blood, urine, faeces, tissues, laboratory cultures)
?
or travelled to a rural environment where contact
burg fever is endemic, i.e., West/Central Africa or South America?
Table 5
Parameters analysed to determine if the patient has disseminated intravascular




Plasma fibrin degradation products
Plasma D-dimer
Plasma coagulation factor II, VII, X (INR)
Plasma coagulation factors II, VII, X (PT)











aPTT, activated partial thromboplastin time; INR, international normalized ratio;
PT, prothrombin time.
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Patients with suspected severe sepsis should be managed
according to standard guidelines.58 These include broad-spectrum
antibiotics, aggressive initial fluid replacement, blood pressure
support if needed, the correction of acidosis, and oxygenation by
intubation and mechanical ventilation as needed. Echocardiogra-
phy is essential to evaluate cardiac function and any vegetations on
the cardiac valves. In the initial stages it is difficult to differentiate
between a viral haemorrhagic fever, severe bacterial sepsis, and
severe malaria.
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